Roche's Tecentriq has become the first checkpoint inhibitor in the world to deliver a benefit to previously-untreated patients with bladder cancer combined with chemotherapy.
The recent phase 3 study from Roche has revealed that Tecentriq, a PD-L1 inhibitor, with platinum-based chemotherapy can reduce the risk of worsening disease or death in patients with locally advanced or metastatic urothelial carcinoma (UC) compared to just chemotherapy alone.
The news from the IMvigor130 trial will now be submitted to regulators across the globe for further analysis, according to the company.
Tecentriq was first approved in 2017 as a first-line treatment option for those with UC – the most common form of bladder cancer – who were unable to receive platinum-based chemotherapy due to other health factors. The National Cancer Institute (NCI) has estimated that these circumstances account for around 50 per cent of all UC patients in the US.
However, the results of the recent study could mean that Tecentriq also becomes available for the patients who can receive chemotherapy, which will significantly increase the number of people eligible for the drug.
Commenting on the results of the phase 3 study, Sandra Horning, chief medical officer at Roche, said: "These results support our broad clinical development programme for Tecentriq in bladder cancer, as well as our approach of combining immunotherapy with chemotherapy or other medicines to improve patient outcomes, and we look forward to discussing them with health authorities."